Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation

Transplantation Proceedings

Volumn 43, Issue 8, 2011, Pages 2950-2953

  Kolonko, A ^a   Chudek, J ^a   Wiecek A ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; EVENING DOSAGE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; URINARY EXCRETION;

ADULT; CREATININE; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 80054745687     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.07.014     Document Type: Conference Paper

References (22)

1. C. Johnson, N. Ahsan, and T. Gonwa Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation Transplantation 69 2000 834
2. A.C. Webster, R. Woodroffe, and R.S. Taylor Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data Br Med J 331 2005 810
3. M.A. Artz, J.M. Boots, and G. Ligtenberg Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus J Am Soc Nephrol 14 2003 1880
4. M.R. First First clinical experience with the new once-daily formulation of tacrolimus Ther Drug Monit 30 2008 159
5. A.J. Butler, P. Roderick, and M. Mullee Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review Transplantation 77 2004 769
6. R.H. Didlake, K. Dreyfus, and R.H. Kerman Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants Transplant Proc 3 suppl 3 1988 63
7. K. Denhaerynck, F. Dobbels, and I. Cleemput Prevalence, consequences, and determinants of nonadherence in adult renal transplant recipients: a literature review Transplant Int 18 2005 1121
8. B.W. Pinsky, S.K. Takemoto, and K.L. Lentine Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression Am J Transplant 9 2009 2597
9. E.M. Vasquez, M. Tanzi, and E. Benedetti Medication noncompliance after kidney transplantation Am J Health-Syst Pharm 60 2003 266
10. R. Alloway, S. Steinberg, and K. Khalil Conversion of stable kidney transplant recipients from a twice daily prograf-based to a once daily modified release tacrolimus-based regimen Transplant Proc 37 2005 867
11. P. Fraile, P. Garcia-Cosmes, and C. Gonzalez Experience in the conversion from Prograf to Advagraf Nephrol Dial Transplant Plus 3 2010 iii539
12. A. Meule, L. Poli, and I. Nofroni Once daily tacrolimus formulation: monitoring of plasma levels, graft fucntion, and cardiovascular risk factors Transplant Proc 42 2010 1317
13. B. Diez Ojea, M. Alonso lvarez, and S. Aguado Fernández Three-month experience with tacrolimus once-daily regimen in stable renal allografts Transplant Proc 41 2009 2323
14. S. Florman, R. Alloway, and M. Kalayoglu Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen Transplant Proc 37 2005 1211
15. F. Tinti, A. Meule, and L. Poli Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients Transplant Proc 42 2010 4047
16. M.R. First, and W.E. Fitzsimmons Modified release tacrolimus Yonsei Med J 45 2004 1127
17. C.A. Böger, P. Rmmele, and M.J. Mihatsch Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity Am J Transplant 6 2006 1963
18. T. Shimizu, H. Ishida, and H. Shirakawa Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts Transplant Proc 40 2008 2370
19. H. Ekberg, C. Bernasconi, and H. Tedesco-Silva Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation Am J Transplant 9 2009 1876
20. J.-M. Hougardy, N. Broeders, and M. Kianda Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure Transplantation 91 2011 566
21. C. Deel, U. Nori, and M.D. Pescovitz Pharmacokinetics of Neoral in stable kidney transplant recipients with long-term diabetes mellitus Transplant Proc 39 2007 109
22. J. Ma, C.K. Rayner, and K.L. Jones Diabetic gastroparesis: diagnosis and management Drugs 69 2009 971